Base de dados : MEDLINE
Pesquisa : D27.505.696.663.050.030 [Categoria DeCS]
Referências encontradas : 7738 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 774 ir para página                         

  1 / 7738 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463865
[Au] Autor:Weant KA; Bailey AM; Baum RA; Justice SB; Calhoun CD
[Ad] Endereço:Pharmacy Services, Medical University of South Carolina, Charleston (Drs Weant and Calhoun); Department of Pharmacy Services, University of Kentucky HealthCare, Lexington (Drs Bailey and Baum); Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington (Drs Bailey and Baum); and Clinical Pharmacy Services, St. Claire Regional Medical Center, Morehead, Kentucky (Dr Justice).
[Ti] Título:Antiemetic Use in the Emergency Department.
[So] Source:Adv Emerg Nurs J;39(2):97-105, 2017 Apr/Jun.
[Is] ISSN:1931-4493
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nausea and vomiting are 2 of the most common complaints of patients presenting to the emergency department (ED). In addition, antiemetics are the most commonly prescribed medications in the ED behind analgesics. Treating these conditions can be complex, especially as one considers that nausea and/or vomiting could be the primary presenting illness or simply a symptom of a more complex etiology. Although there is a wide variety of pharmacotherapeutic options in the armamentarium to treat these conditions, very few consensus recommendations exist to help guide the use of antiemetic agents in the ED, leading to wide variability in medication use. Contributing to these variations in practice is the extended spectrum of etiologies and potential physiological factors that contribute to the development of nausea or vomiting. A thorough understanding of the pharmacology and administration of these agents can help practitioners devise tailored antiemetic regimens based upon the underlying etiology.
[Mh] Termos MeSH primário: Antieméticos/uso terapêutico
Serviço Hospitalar de Emergência
Náusea/prevenção & controle
Vômito/prevenção & controle
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiemetics)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM; N
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1097/TME.0000000000000141


  2 / 7738 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29371217
[Au] Autor:Jarvis S; Dassan P; Piercy CN
[Ad] Endereço:Imperial College Healthcare NHS Trust, London W12 0HS, UK sheba.jarvis@imperial.ac.uk.
[Ti] Título:Managing migraine in pregnancy.
[So] Source:BMJ;360:k80, 2018 01 25.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Enxaqueca com Aura/tratamento farmacológico
Complicações na Gravidez/tratamento farmacológico
[Mh] Termos MeSH secundário: Acetaminofen/uso terapêutico
Adulto
Analgésicos não Entorpecentes/uso terapêutico
Antieméticos/uso terapêutico
Feminino
Seres Humanos
Gravidez
Sumatriptana/uso terapêutico
Vasoconstritores/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Non-Narcotic); 0 (Antiemetics); 0 (Vasoconstrictor Agents); 362O9ITL9D (Acetaminophen); 8R78F6L9VO (Sumatriptan)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180127
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k80


  3 / 7738 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29424979
[Au] Autor:Germes-Piña F; Acosta-Orozco DM; Flores-Franco RA; Verdugo-Castro PN
[Ti] Título:[Pneumomediastinum associated with hyperemesis gravidarum: a case report].
[Ti] Título:Neumomediastino secundario a hiperémesis gravídica: reporte de un caso..
[So] Source:Ginecol Obstet Mex;84(9):586-92, 2016 Sep.
[Is] ISSN:0300-9041
[Cp] País de publicação:Mexico
[La] Idioma:spa
[Ab] Resumo:Background: The hyperemesis gravidarum is a severe illness of nauseas and vomit that is present in the first trimester of the pregnancy, it has an incidence of 0.3 to 2%, it has been associated to weight loss, electrolytic disturbances, ketonuria, dehydration and in very seldom cases spontaneous pneumomediastinum. Clinical case: A 21 years old female patient, primigest, in the first trimester of gestation, she started her disease with nauseas and vomiting more than 15 times during 6 hours period, odynophagia, dysphonia and pain in the cervical region, loss of 5 kilograms in the last month. The physical examination showed the patient in bad conditions, dehydration, neck with volume increased and emphysema subcutaneus, crakles until torax. Laboratory findings with hypokalemia, leukocytosis, acute kidney failure, and elevation of hepatic enzymes. The initial treatment was with intravenous fluids resuscitation, hydroelectrolytic balance restoration, antiemetic treatment and rest, it was taken TC of neck and torax, and was exclude any laryngeal and esophageal injury and perforation, but it showed air in the mediastinum. Conservative management with favorable evolution and completed resolution in 7 days. Conclusion: It is very important that the medical doctor must keep in mind the different diagnosis of and take an opportune decision in case of present those complications potentially fatal to the mother.
[Mh] Termos MeSH primário: Hiperêmese Gravídica/complicações
Enfisema Mediastínico/etiologia
Complicações na Gravidez/diagnóstico
[Mh] Termos MeSH secundário: Antieméticos/administração & dosagem
Diagnóstico Diferencial
Feminino
Hidratação/métodos
Seres Humanos
Hiperêmese Gravídica/diagnóstico
Hiperêmese Gravídica/terapia
Enfisema Mediastínico/diagnóstico
Enfisema Mediastínico/terapia
Gravidez
Complicações na Gravidez/terapia
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiemetics)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE


  4 / 7738 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29368823
[Au] Autor:Ritchie MK; Ellison M; Ranganathan P; Sizemore D; Vallejo MC
[Ti] Título:Aprepitant: A Novel Medicaton in the Prevention of Postoperative Nausea and Vomiting.
[So] Source:W V Med J;112(6):20-4, 2016 Nov-Dec.
[Is] ISSN:0043-3284
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Antieméticos/uso terapêutico
Morfolinas/uso terapêutico
Náusea e Vômito Pós-Operatório/tratamento farmacológico
Náusea e Vômito Pós-Operatório/prevenção & controle
[Mh] Termos MeSH secundário: Antieméticos/farmacologia
Seres Humanos
Incidência
Morfolinas/farmacologia
Náusea e Vômito Pós-Operatório/epidemiologia
Medição de Risco
Fatores de Risco
West Virginia/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiemetics); 0 (Morpholines); 1NF15YR6UY (aprepitant)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE


  5 / 7738 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374715
[Au] Autor:Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
[Ad] Endereço:Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
[Ti] Título:Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
[So] Source:Anticancer Res;38(2):877-884, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Chemotherapy-induced nausea and vomiting (CINV) is one of most distressing adverse events during cancer chemotherapy. In breast cancer patients receiving anthracycline and cyclophosphamide (AC) chemotherapy, CINV is poorly controlled. PATIENTS AND METHODS: The prevalence of guideline-consistent antiemetic medication and control of CINV were investigated retrospectively in breast cancer patients receiving the first cycle of AC chemotherapy. Risks for CINV were analyzed by the multivariate logistic regression analysis. The effect of olanzapine added to the standard antiemetic medication on the incidence of CINV was subsequently evaluated in separate patients who received the first cycle of AC chemotherapy. RESULTS: Although the guideline-consistent antiemetic medication was performed in all subjects, the control rate of nausea (32%), but not vomiting (78%) was low. Risk analysis indicated that age younger than 55-year-old was a significant factor that reduces the control of both nausea and vomiting. Olanzapine (5 mg/day for 5 days), when added to the standard three-drug antiemetic medication, significantly improved the control of nausea and complete response. CONCLUSION: CINV was poorly controlled in breast cancer patients receiving AC chemotherapy, in which age younger than 55-year-old was a significant risk for both nausea and vomiting. Olanzapine was effective for improvement of the control of CINV associated with AC chemotherapy. Therefore, care should be taken to prevent CINV in young patients receiving AC chemotherapy by adding olanzapine to the standard three-drug antiemetic medication.
[Mh] Termos MeSH primário: Antieméticos/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Benzodiazepinas/administração & dosagem
Neoplasias da Mama/tratamento farmacológico
Náusea/tratamento farmacológico
Vômito/tratamento farmacológico
[Mh] Termos MeSH secundário: Fatores Etários
Antraciclinas/administração & dosagem
Antraciclinas/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Ciclofosfamida/administração & dosagem
Ciclofosfamida/efeitos adversos
Feminino
Seres Humanos
Meia-Idade
Náusea/induzido quimicamente
Náusea/prevenção & controle
Estudos Retrospectivos
Vômito/induzido quimicamente
Vômito/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anthracyclines); 0 (Antiemetics); 12794-10-4 (Benzodiazepines); 8N3DW7272P (Cyclophosphamide); N7U69T4SZR (olanzapine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  6 / 7738 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29280884
[Au] Autor:Manahan MA; Johnson DJ; Gutowski KA; Bonawitz SC; Ellsworth WA; Zielinski M; Thomsen RW; Basu CB
[Ad] Endereço:Baltimore, Md.; Sacramento, Calif.; Chicago and Arlington Heights, Ill.; and Houston, Texas From Johns Hopkins Plastic and Reconstructive Surgery; Sacramento Plastic and Reconstructive Surgery Medical Group, Inc.; Chicago Cosmetic Institute and University; The Johns Hopkins Outpatient Clinic; Houston Methodist West Hospital; the American Society of Plastic Surgeons; The Johns Hopkins University School of Medicine; and the Basu Center for Aesthetics and Plastic Surgery.
[Ti] Título:Postoperative Nausea and Vomiting with Plastic Surgery: A Practical Advisory to Etiology, Impact, and Treatment.
[So] Source:Plast Reconstr Surg;141(1):214-222, 2018 01.
[Is] ISSN:1529-4242
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Ambulatory surgery is common in plastic surgery, where many aesthetic and reconstructive procedures can be performed in hospitals, ambulatory surgery centers, or office-based surgery facilities. Outpatient surgery offers advantages to both the patient and the surgeon by increasing accessibility, flexibility, and convenience; lowering cost; and maintaining high-quality care. To optimize a patient's experience and comfort, postoperative nausea and vomiting (PONV) should be prevented. However, in those patients who develop PONV, it must be appropriately managed and treated. The incidence of PONV is variable. It is often difficult to accurately predict those patients who will develop PONV or how they will manifest symptoms. There are a variety of recommended "cocktails" for PONV prophylaxis and treatments that are potentially effective. The decision regarding the type of treatment given is often more related to provider preference and determination of side-effect profile, rather than targeted to specific patient characteristics, because of the absence of large volumes of reliable data to support specific practices over others. Fortunately, there are several tenets for the successful prevention and treatment of PONV we have extracted from the literature and summarize here. The following is a summary for the practicing plastic surgeon of the current state of the literature regarding PONV cause, risk factors, prophylaxis, and treatment that may serve as a guide for further study and practice management.
[Mh] Termos MeSH primário: Antieméticos/uso terapêutico
Náusea e Vômito Pós-Operatório/tratamento farmacológico
Náusea e Vômito Pós-Operatório/prevenção & controle
Procedimentos Cirúrgicos Reconstrutivos/efeitos adversos
Cirurgia Plástica/efeitos adversos
[Mh] Termos MeSH secundário: Procedimentos Cirúrgicos Ambulatórios/efeitos adversos
Procedimentos Cirúrgicos Ambulatórios/métodos
Feminino
Seguimentos
Seres Humanos
Masculino
Procedimentos Cirúrgicos Reconstrutivos/métodos
Índice de Gravidade de Doença
Cirurgia Plástica/métodos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiemetics)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180117
[Lr] Data última revisão:
180117
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1097/PRS.0000000000003924


  7 / 7738 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266076
[Au] Autor:Committee on Practice Bulletins-Obstetrics
[Ti] Título:ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy.
[So] Source:Obstet Gynecol;131(1):e15-e30, 2018 01.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nausea and vomiting of pregnancy is a common condition that affects the health of a pregnant woman and her fetus. It can diminish a woman's quality of life and also significantly contributes to health care costs and time lost from work (1, 2). Because morning sickness is common in early pregnancy, the presence of nausea and vomiting of pregnancy may be minimized by obstetricians, other obstetric care providers, and pregnant women and, thus, undertreated (1). Furthermore, some women do not seek treatment because of concerns about the safety of medications (3). Once nausea and vomiting of pregnancy progresses, it can become more difficult to control symptoms. Treatment in the early stages may prevent more serious complications, including hospitalization (4). Safe and effective treatments are available for more severe cases, and mild cases of nausea and vomiting of pregnancy may be resolved with lifestyle and dietary changes. The woman's perception of the severity of her symptoms plays a critical role in the decision of whether, when, and how to treat nausea and vomiting of pregnancy. Nausea and vomiting of pregnancy should be distinguished from nausea and vomiting related to other causes. The purpose of this document is to review the best available evidence about the diagnosis and management of nausea and vomiting of pregnancy.
[Mh] Termos MeSH primário: Antieméticos/administração & dosagem
Saúde Materna
Êmese Gravídica/prevenção & controle
Guias de Prática Clínica como Assunto
Primeiro Trimestre da Gravidez
[Mh] Termos MeSH secundário: Comitês Consultivos/normas
Antieméticos/farmacologia
Medicina Baseada em Evidências
Feminino
Seres Humanos
Êmese Gravídica/tratamento farmacológico
Náusea/tratamento farmacológico
Náusea/fisiopatologia
Obstetrícia/normas
Gravidez
Resultado da Gravidez
Índice de Gravidade de Doença
Estados Unidos
Vômito/tratamento farmacológico
Vômito/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antiemetics)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002456


  8 / 7738 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29280885
[Au] Autor:Lalonde DH
[Ad] Endereço:Saint John, New Brunswick, Canada From the Division of Plastic Surgery, Dalhousie University.
[Ti] Título:Discussion: Postoperative Nausea and Vomiting with Plastic Surgery: A Practical Advisory to Etiology, Impact, and Treatment.
[So] Source:Plast Reconstr Surg;141(1):223-224, 2018 01.
[Is] ISSN:1529-4242
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Náusea e Vômito Pós-Operatório
Cirurgia Plástica
[Mh] Termos MeSH secundário: Antieméticos
Método Duplo-Cego
Seres Humanos
Procedimentos Cirúrgicos Reconstrutivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Antiemetics)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1097/PRS.0000000000003925


  9 / 7738 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266070
[Ti] Título:ACOG Practice Bulletin No. 189 Summary: Nausea And Vomiting Of Pregnancy.
[So] Source:Obstet Gynecol;131(1):190-193, 2018 Jan.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nausea and vomiting of pregnancy is a common condition that affects the health of a pregnant woman and her fetus. It can diminish a woman's quality of life and also significantly contributes to health care costs and time lost from work (1, 2). Because morning sickness is common in early pregnancy, the presence of nausea and vomiting of pregnancy may be minimized by obstetricians, other obstetric care providers, and pregnant women and, thus, undertreated (1). Furthermore, some women do not seek treatment because of concerns about the safety of medications (3). Once nausea and vomiting of pregnancy progresses, it can become more difficult to control symptoms. Treatment in the early stages may prevent more serious complications, including hospitalization (4). Safe and effective treatments are available for more severe cases, and mild cases of nausea and vomiting of pregnancy may be resolved with lifestyle and dietary changes. The woman's perception of the severity of her symptoms plays a critical role in the decision of whether, when, and how to treat nausea and vomiting of pregnancy. Nausea and vomiting of pregnancy should be distinguished from nausea and vomiting related to other causes. The purpose of this document is to review the best available evidence about the diagnosis and management of nausea and vomiting of pregnancy.
[Mh] Termos MeSH primário: Antieméticos/administração & dosagem
Êmese Gravídica/diagnóstico
Êmese Gravídica/tratamento farmacológico
Guias de Prática Clínica como Assunto
Resultado da Gravidez
[Mh] Termos MeSH secundário: Comitês Consultivos
Medicina Baseada em Evidências
Feminino
Seres Humanos
Náusea/tratamento farmacológico
Náusea/fisiopatologia
Gravidez
Primeiro Trimestre da Gravidez
Medição de Risco
Índice de Gravidade de Doença
Estados Unidos
Vômito/tratamento farmacológico
Vômito/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiemetics)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002450


  10 / 7738 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29187462
[Au] Autor:Fujii H; Iihara H; Kajikawa N; Kobayashi R; Suzuki A; Tanaka Y; Yamaguchi K; Yoshida K; Itoh Y
[Ad] Endereço:Department of Pharmacy, Gifu University Hospital, Gifu, Japan h_fujii@gifu-u.ac.jp.
[Ti] Título:Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy.
[So] Source:Anticancer Res;37(12):6831-6837, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cisplatin is commonly used for esophageal and gastric cancer, but has a high emetic risk. Although the control of vomiting is favorable, nausea is still poorly controlled in patients receiving cisplatin-based regimens. The present study was designed to determine the risks for cisplatin-induced nausea. The effect of olanzapine, an antipsychotic drug, as an antiemetic for patients with risk of poor control of nausea was subsequently examined. PATIENTS AND METHODS: The prevalence of antiemetic medication and the control of nausea and vomiting were retrospectively examined in patients with esophageal or gastric cancer receiving the first cycle of cisplatin-based chemotherapy. Risks for nausea were analyzed by multivariate logistic regression analysis, in which threshold for age and cisplatin dose wer assessed by receiver operating characteristic curve analysis. RESULTS: A total of 186 patients received cisplatin-based regimens during January 2011 and December 2016. Guideline-consistent antiemetic medication was administered to all patients. Although the rate of no vomiting was high (93%), the rate of non-significant (grade 2 or more) nausea was insufficient (64%) during the overall period. Risk analysis showed that cisplatin dose of 50 mg/m or more and female gender were significant risks for nausea. Addition of olanzapine, but not of prochlorperazine, to the standard antiemetic medication was effective in suppressing nausea in patients who experienced nausea in the first cycle. CONCLUSION: Being female and cisplatin doses at 50 mg/m or more were demonstrated to increase risk for nausea. Addition of olanzapine to the standard medication was effective in preventing nausea in high-risk patients with esophageal and gastric cancer.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Benzodiazepinas/uso terapêutico
Neoplasias Esofágicas/tratamento farmacológico
Náusea/prevenção & controle
Neoplasias Gástricas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antieméticos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Cisplatino/administração & dosagem
Cisplatino/efeitos adversos
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
Análise Multivariada
Náusea/induzido quimicamente
Estudos Retrospectivos
Fatores de Risco
Fatores Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiemetics); 12794-10-4 (Benzodiazepines); N7U69T4SZR (olanzapine); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE



página 1 de 774 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde